MONTVALE, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) today announced that a conference call will be held on Friday, February 20, 2026, at 11:00 AM Eastern Time (ET) to review fourth quarter and full year 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. Fourth quarter and full year 2025 results will be published prior to the market opening on Friday, February 20, 2026. The press release, and its accompanying fin ...

If you like to see more ideas, please subscribe to the premium service "Value in Corporate Events" here and try the free trial. In this service we cover major earnings events, M&A, IPOs and other significant corporate events with actionable ideas. Furthermore, we provide coverage of situations and names on request!Over the summer of 2025, I called Balchem ( BCPC ) a healthy long-term player, stressing the word long-term. A high-quality and niche market leader has seen a return to growth, yet being awarded e ...

MONTVALE, N.J., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will attend the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer and Allison Baurichter, Senior Director Investor Relations will attend the conference. About Balchem Corpora ...

EU producers laud EU for addressing choline chloride dumping by China; measures will help preserve jobs and secure feed supply chainMONTVALE, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- As producers of choline chloride in the EU, Eastman and Balchem welcome the European Union's decision published on December 19, 2025 to adopt anti-dumping duties between 90.0 and 115.9% on choline chloride imports from the People's Republic of China. This decision, which will be effective for five years with the possibility of r ...

Core Insights - Balchem, a leader in specialty ingredients for food, pharmaceutical, and animal health markets, reported significant insider selling activity by Director David B Fischer [1][2]. Transaction Summary - On December 3, 2025, David B Fischer sold 8,000 common shares for a total of $1,231,748.20, following the exercise of 6,000 fully vested options [2][3]. - Post-transaction, Fischer's direct share count decreased by 50%, from 15,989 to 7,989 shares, representing approximately 0.025% of shares outstanding [6]. - The weighted average sale price was $153.97, closely aligning with the market closing price of $156.2 on December 12, 2025 [6]. Company Overview - Balchem reported a total revenue of $1.01 billion and a net income of $149.2 million for the trailing twelve months (TTM) [5]. - The company has a dividend yield of 0.61% and experienced a 1-year price change of -12.4% [5]. Business Operations - Balchem specializes in providing ingredients for human nutrition, animal nutrition, and specialty industrial applications, including microencapsulated nutrients and sterilization agents [7]. - The company serves various sectors, including food and beverage manufacturers, pharmaceutical companies, and agricultural businesses, both domestically and internationally [7]. Strategic Initiatives - Balchem is investing in growth by building a new facility for producing microencapsulated food ingredients and nutraceuticals, which will more than double its current capacity [11]. - This investment is a response to increasing demand, indicating potential for continued business growth [12]. Recent Developments - Following the insider selling, Balchem announced a 10.3% dividend increase, marking the 17th consecutive annual dividend increase [10]. - The company also reported record quarterly sales, which increased by 11.5% year over year [11].

Core Viewpoint - Balchem Corporation announced a dividend of $0.96 per share, marking a 10.3% increase from the previous year, reflecting strong financial performance and commitment to shareholder returns [1][2]. Company Overview - Balchem Corporation develops, manufactures, and markets specialty ingredients aimed at enhancing health and well-being across various industries [2]. - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2]. - The Human Nutrition & Health segment focuses on customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical applications [2]. - The Animal Nutrition & Health segment supplies products to various animal health markets [2]. - Specialty Products offers specialty-packaged chemicals for healthcare and other industries, as well as chelated minerals for the agricultural market [2]. Dividend Announcement - The Board of Directors declared a dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record by December 23, 2025 [1]. - This dividend represents the seventeenth consecutive increase, showcasing the company's consistent financial performance and the Board's confidence in long-term strategies [2].

Core Insights - Balchem Corporation will present at Baird's 55th Annual Global Industrial Conference on November 12, 2025, with key executives participating [1] Company Overview - Balchem Corporation is a global specialty ingredient manufacturer focused on health and nutrition markets, offering solutions across various industries [2] - The company operates through three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2] - The Human Nutrition & Health segment provides customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical applications [2] - The Animal Nutrition & Health segment supplies products to various animal health markets [2] - Specialty Products segment offers specialty-packaged chemicals for healthcare and other industries, including chelated minerals for the agricultural market [2]

Group 1 - Balchem Corporation will present at Baird's 55th Annual Global Industrial Conference on November 12, 2025, with key executives including the Chairman, CEO, and CFO participating [1] - The company operates in three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products [2] - The Human Nutrition & Health segment focuses on customized food and beverage ingredient systems and key nutrients for food, supplement, and pharmaceutical applications [2] Group 2 - The Animal Nutrition & Health segment supplies products to various animal health markets [2] - Through its Specialty Products segment, Balchem provides specialty-packaged chemicals for healthcare and other industries, as well as chelated minerals for the agricultural market [2]

Core Insights - The article focuses on the Asia Value & Moat Stocks research service, which targets value investors looking for significant discrepancies between stock prices and intrinsic values, particularly in the Asian market [1] Group 1: Investment Strategy - The service emphasizes deep value balance sheet bargains, such as net cash stocks, net-nets, low price-to-book (P/B) stocks, and sum-of-the-parts discounts [1] - It also highlights wide moat stocks, which are characterized by strong earnings power at discounted prices, including high-quality businesses and hidden champions [1] Group 2: Market Focus - The primary focus of the investment ideas is on stocks listed in Asia, with a particular emphasis on the Hong Kong market [1] - The service provides a range of watch lists with monthly updates to assist investors in identifying potential opportunities [1]

Core Insights - Balchem Corporation, a significant player in the specialty chemicals industry, reported record third-quarter sales despite a challenging year, leading to a 5% rise in stock price [1][6] Financial Performance - On October 21, 2025, Balchem reported earnings per share (EPS) of $1.23, missing the estimated $1.36, which represents a slight negative earnings surprise of -0.74%. However, this EPS shows growth compared to the previous year's $1.03 [2] - The company's revenue reached $267.6 million, surpassing the estimated $258.3 million, marking an 11.5% increase from last year's $239.94 million [2] Valuation Metrics - Balchem's price-to-earnings (P/E) ratio is 34.56, indicating strong investor confidence in future earnings [3][6] - The price-to-sales ratio stands at 5.05, reflecting the market's valuation of its revenue [3] - The enterprise value to sales ratio is 5.17, suggesting a strong market valuation relative to sales [3] - The enterprise value to operating cash flow ratio is 26.00, providing insight into its valuation concerning cash flow from operations [4] - The earnings yield is 2.89%, showing the percentage of each dollar invested that was earned [4] - The debt-to-equity ratio is low at 0.15, indicating conservative debt use [4][6] Liquidity and Cash Flow - Balchem's current ratio of 2.72 suggests a strong ability to cover short-term liabilities with short-term assets [5] - The company generated $51 million in free cash flow, which helped reduce debt [5] Market Sentiment - Despite the positive financial performance, Balchem's stock has remained relatively stagnant, indicating that investors are anticipating further results [5][6]